Their primary role in metabolic regulation involves stimulating insulin secretion from pancreatic beta cells while inhibiting glucagon release
Quick Stats for GLP-1 Diabetes Treatment Drugs Market GLP-1 Diabetes Treatment Drugs Market Value (2025): USD 6,556.5 million GLP-1 Diabetes Treatment Drugs Market Forecast Value (2035): USD 62,543.2 million GLP-1 Diabetes Treatment Drugs Market Forecast CAGR: 25.3% Leading Drug Type in GLP-1 Diabetes Treatment Drugs Market: Liraglutide (35.5%) Key Growth Regions in GLP-1 Diabetes Treatment Drugs Market: Asia Pacific, North America, and Europe Top Key Players in GLP-1 Diabetes Treatment Drugs Market: Eli Lilly, Sanofi, Novo Nordisk, Hanmi Pharmaceutical Co., Boehringer Ingelheim, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline (GSK), Ganli Pharmaceuticals, Tonghua Dongbao, Shanghai Renhui Biopharmaceuticals Co., Ltd., Huadong Medicine, Page Biopharmaceuticals, Jiangsu Hausen Pharmaceuticals Group Co., Ltd
Henninot, J
Sillj, Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A
Follow FDA guidelines for safe sharps disposal
Increasing metabolism and helping to optimize blood sugar, through Semaglutide peptide therapy